Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 188 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

 		VEXAS Syndrome Phase2 Japan NCT07748624

A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

 		Complement 3 Glomerulopathy Spain NCT07598448

Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

 		Coronary Artery Disease Phase2 Australia NCT07830719

A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia

 		Spinal Muscular Atrophy Saudi Arabia NCT07737756

A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants

 		Healthy Participants Phase1 United Kingdom NCT07783503

ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

 		Spinal Muscular Atrophy Phase4 United States NCT07448610

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

 		Moderate to Severe Psoriatic Arthritis Phase2 United States NCT07801495

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)

 		Uncomplicated Plasmodium Falciparum Malaria Phase2 Burkina Faso
Côte d’Ivoire
Rwanda 		NCT07811908

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

 		Chronic Pruritus of Unknown Origin Phase3 United States NCT07811869

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

 		Chronic Pruritus of Unknown Origin Phase3 Canada
Japan
South Korea
United States
View all
 NCT07700056